利索-全球专利检索

  1. 登录
  2. 注册
发明授权
CN101063123B 人C-型利尿钠肽与人血清白蛋白的融合蛋白的制备方法及产品 失效 - 权利终止 转让

人C-型利尿钠肽与人血清白蛋白的融合蛋白的制备方法及产品
摘要：
人C-型利尿钠肽(CNP)与人血清白蛋白(HSA)的融合蛋白的制备方法及产品，属于长效重组融合蛋白药物技术领域。本发明利用重叠PCR技术，将HSA cDNA和CNP cDNA进行拼接，中间不加入任何连接肽，得到的HSA-CNP cDNA融合基因被整合到宿主的染色体中，在宿主系统中进行表达。本发明的融合蛋白包括与人血清白蛋白至少85％序列同源的第一区和与人C-型利尿钠肽至少85％序列同源的第二区，该融合蛋白可以在不改变融合蛋白特性的前提下，进行个别氨基酸残基的取代、缺失或加入。本发明的融合蛋白在保持了人C-型利尿钠肽的生理特性的基础上延长其在体内的半衰期，改善其溶解度，在药学领域有良好的应用前景。
摘要（英）：

The invention discloses a preparing method of fusion protein of human C-type natriuretic peptide (CNP) and human serum albumin (HSA) and product, belonging to the technical field of long-acting recombinant fusion protein drug, which comprises the following steps: adopting overlapping PCR technique; splitting HSA cDNA and CNP cDNA; integrating HSA-CNP cDNA fusion gene obtained without any connecting peptide being added into chromosome of a host; and expressing in the host system. The fusion protein of the invention includes a first area with at least 85% sequence homologous with human serum albumin and the second area with at least 85% sequence homologous with human C-type natriuretic peptide, individual amino acid residue substitution, deletion and addition can be carried out with the characteristics of the fusion protein being not changed.The fusion protein of the invention has extended half-life in the human body, with the physiological property of the human C-type natriuretic peptide being kept, improved solvability, and good application prospect in medical field.

公开/授权文献
0/0